✦ LIBER ✦

Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide – Analyses from a randomised, placebo-controlled study

✍ Scribed by Jeppesen, P.B.; Pertkiewicz, M.; Forbes, A.; Pironi, L.; Gabe, S.M.; Joly, F.; Messing, B.; Loth, S.; Youssef, N.N.; Heinze, H.; Berghöfer, P.

Book ID: 122642997
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 496 KB
Volume: 32
Category: Article
ISSN: 0261-5614
DOI: 10.1016/j.clnu.2013.03.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

OP017 TEDUGLUTIDE, A GLUCAGON-LIKE PEPTI

OP017 TEDUGLUTIDE, A GLUCAGON-LIKE PEPTIDE 2 (GLP-2)-ANALOGUE, ENABLES SIGNIFICANT REDUCTIONS IN PARENTERAL SUPPORT IN PATIENTS WITH SHORT BOWEL SYNDROME (SBS): RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, MULTINATIONAL PHASE III STUDY (STEPS)

✍ M. Pertkiewicz; B. Messing; A. Forbes; S.J. O'Keefe; B. Joelsson; S. Wolf; P.B. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Clinical trial: the glucagon-like peptid

Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study

✍ P. M. HELLSTRÖM; J. HEIN; P. BYTZER; E. BJÖRNSSÖN; J. KRISTENSEN; H. SCHAMBYE 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB

Teduglutide, a Novel Analogue of Glucago

Teduglutide, a Novel Analogue of Glucagon-like Peptide 2 (GLP-2), Is Effective and Safe in Reducing Parenteral Support Volume in Short Bowel Syndrome–Intestinal Failure Subjects: Results From a 24-Week, Placebo-Controlled Phase 3 Trial (STEPS)

✍ Palle B. Jeppesen; Marek Pertkiewicz; Douglas L. Seidner; Stephen O'Keefe; Hartm 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 192 KB

Acute effects of continuous infusions of

Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study

✍ Madsen, K.B.; Askov-Hansen, C.; Naimi, R.M.; Brandt, C.F.; Hartmann, B.; Holst, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 267 KB

The effects of LY2189265, a long-acting

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study

✍ G. E. Umpierrez; T. Blevins; J. Rosenstock; C. Cheng; J. H. Anderson; E. J. Bast 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 652 KB